DIPG-21. GENOMIC LANDSCAPE OF THE FIRST 100 TUMORS REGISTERED IN THE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL

BACKGROUND: Genomic analyses of DIPG have been so far mostly performed on autopsy samples or in retrospective studies. In the frame of the BIOMEDE randomized trial of three targeted therapies (erlotinib, everolimus, dasatinib) based on three biomarkers (EGFR, PTEN and PDGFRA respectively), a systema...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Castel, David, Barret, Emilie, Picot, Stephanie, Plessier, Alexandre, Le Dret, Ludivine, Nysom, Karsten, Huybrechts, Sophie, Capolino, Perrine, Le Deley, Marie-Cecile, Vassal, Gilles, Puget, Stephanie, Varlet, Pascale, Grill, Jacques, Debily, Marie-Anne
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2017
Предметы:
Abstracts
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475015/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.036
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы